Why ESSA Pharma, AnaptysBio And More Are Moving Today
Why ESSA Pharma, AnaptysBio And More Are Moving Today
ESSA Pharma Inc. (NASDAQ:EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced forms of prostate cancer at ASCO Genitourinary Cancers Symposium.
ESSA 制药公司 （纳斯达克：EPIX）该公司公布了第一季度财报，并在ASCO泌尿生殖系统癌症研讨会上重点介绍了 EPI-7386 晚期前列腺癌的第一阶段药理学数据，此后，股价走高。
ESSA Pharma engages in the development of small molecule drugs for prostate cancer. Realm is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies.
ESSA Pharma从事治疗前列腺癌的小分子药物的开发。Realm 是一家新兴的专业生物制药公司，专注于开发新的免疫调节疗法。
ESSA Pharma stock was up 41.25% at $27.36. The stock has a 52-week high of $32.69 and a 52-week low of $3.
ESSA Pharma股价上涨41.25％，至27.36美元。该股创下52周高点32.69美元，52周低点为3美元。
Pacific Biosciences Of California (NASDAQ:PACB) shares are trading higher after the company reported better-than-expected 4 EPS and sales results.
加州太平洋生物科学 （纳斯达克：PACB）在该公司公布的每股收益和销售业绩好于预期后，股价上涨。
Piper Sandler also upgraded the stock from Neutral to Overweight and raised its price target from $20 to $52 per share.
派珀·桑德勒还将该股从中性上调至增持，并将目标股价从每股20美元上调至52美元。
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems.
加州太平洋生物科学公司是一家生物技术公司，专注于生物研究工具的设计、开发和商业化。该公司开发测序系统以帮助解决遗传复杂的问题。
Pacific Biosciences stock was up 14.18% at $52.41. The stock has a 52-week high of $53.69 and a 52-week low of $2.20.
太平洋生物科学股价上涨14.18％，至52.41美元。该股创下52周高点53.69美元，52周低点为2.20美元。
AnaptysBio (NASDAQ:ANAB) shares are trading higher after JP Morgan upgraded the stock from Underweight to Overweight and raised its price target from $19 to $40 per share.
AnaptysBio （纳斯达克：ANAB）摩根大通将股票从减持上调至增持并将目标股价从每股19美元上调至40美元之后，股价走高。
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
AnaptysBio Inc是一家处于临床阶段的生物技术公司。它专注于开发候选抗体产品，以满足炎症和免疫肿瘤学领域未得到满足的医疗需求。该公司使用其专有的抗体发现技术平台开发针对新兴生物靶点的候选产品，该平台旨在在体外复制抗体生成的自然过程。
AnaptysBio stock was up 11.58% at $33.14. The stock has a 52-week high of $34.24 and a 52-week low of $12.06.
AnaptysBio的股票上涨了11.58％，至33.14美元。该股创下52周高点34.24美元，52周低点12.06美元。
Vanda Pharmaceuticals (NASDAQ:VNDA) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales results.
万达制药 （纳斯达克：VNDA）在该公司公布的第四季度每股收益和销售业绩好于预期后，股价上涨。
Vanda Pharmaceuticals Inc is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
Vanda Pharmicals Inc从事疗法的开发和商业化，以满足高度未得到满足的医疗需求并改善患者的生活。其产品组合包括 HETLIOZ、Fanapt、Tradipitant (VLY-686)、VTR-297 和 VQW-765。
Vanda Pharmaceuticals stock was up 21.77% at $18.76. The stock has a 52-week high of $19.25 and a 52-week low of $7.12.
万达制药股价上涨21.77％，至18.76美元。该股创下52周高点19.25美元，52周低点7.12美元。
译文内容由第三方软件翻译。